Iverson GM - Search Results

1

Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI.

Iverson GM, von Mühlen CA, Staub HL, Lassen AJ, Binder W, Norman GL. Iverson GM, et al. J Autoimmun. 2006 Dec;27(4):266-71. doi: 10.1016/j.jaut.2006.09.007. Epub 2006 Oct 31. J Autoimmun. 2006. PMID: 17081732

2

IgA antibodies to beta2-glycoprotein I and atherosclerosis.

Staub HL, Franck M, Ranzolin A, Norman GL, Iverson GM, von Mühlen CA. Staub HL, et al. Among authors: iverson gm. Autoimmun Rev. 2006 Dec;6(2):104-6. doi: 10.1016/j.autrev.2006.06.014. Epub 2006 Jul 24. Autoimmun Rev. 2006. PMID: 17138253 Review. No abstract available.

3

Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies.

Iverson GM, Reddel S, Victoria EJ, Cockerill KA, Wang YX, Marti-Renom MA, Sali A, Marquis DM, Krilis SA, Linnik MD. Iverson GM, et al. J Immunol. 2002 Dec 15;169(12):7097-103. doi: 10.4049/jimmunol.169.12.7097. J Immunol. 2002. PMID: 12471146 Free article.

4

The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI autoantibodies by ELISA.

Iverson GM, Matsuura E, Victoria EJ, Cockerill KA, Linnik MD. Iverson GM, et al. J Autoimmun. 2002 Jun;18(4):289-97. doi: 10.1006/jaut.2002.0590. J Autoimmun. 2002. PMID: 12144810

5

Therapeutic potential of toleragens in the management of antiphospholipid syndrome.

Cockerill KA, Iverson GM, Jones DS, Linnik MD. Cockerill KA, et al. Among authors: iverson gm. BioDrugs. 2004;18(5):297-305. doi: 10.2165/00063030-200418050-00002. BioDrugs. 2004. PMID: 15377172 Review.

6

Advances in understanding what we measure when detecting anticardiolipin autoantibodies.

Iverson GM, Victoria EJ, Cockerill KA, Linnik MD. Iverson GM, et al. Clin Chim Acta. 2004 May;343(1-2):37-44. doi: 10.1016/j.cccn.2004.01.008. Clin Chim Acta. 2004. PMID: 15115676 Review.

7

Detection and characterization of B cell epitopes on beta2-glycoprotein I.

Cockerill KA, Linnik MD, Iverson GM. Cockerill KA, et al. Among authors: iverson gm. Clin Immunol. 2004 Aug;112(2):129-35. doi: 10.1016/j.clim.2004.02.011. Clin Immunol. 2004. PMID: 15240155 Review.

8

Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V.

Shi T, Giannakopoulos B, Yan X, Yu P, Berndt MC, Andrews RK, Rivera J, Iverson GM, Cockerill KA, Linnik MD, Krilis SA. Shi T, et al. Among authors: iverson gm. Arthritis Rheum. 2006 Aug;54(8):2558-67. doi: 10.1002/art.21968. Arthritis Rheum. 2006. PMID: 16868978 Free article.

9

Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI.

Iverson GM, Victoria EJ, Marquis DM. Iverson GM, et al. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15542-6. doi: 10.1073/pnas.95.26.15542. Proc Natl Acad Sci U S A. 1998. PMID: 9861005 Free PMC article.

10

A chemically defined, toleragen-based approach for targeting anti-beta2-glycoprotein I antibodies.

Iverson GM, Jones DS, Marquis D, Linnik MD, Victoria EJ. Iverson GM, et al. Lupus. 1998;7 Suppl 2:S166-9. doi: 10.1177/096120339800700236. Lupus. 1998. PMID: 9814697

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results